Drug intelligence & clinical pharmacy
-
Drug Intell Clin Pharm · Feb 1982
Case ReportsAcquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine.
Two patients developed symptomatic methemoglobinemia and hemolytic anemia after treatment with phenazopyridine. Methemoglobinemia appears to be a rare occurrence after commonly used doses of phenazopyridine; phenazopyridine-associated hemolytic anemia has been reported both after overdose and after usual doses. ⋯ Aniline-induced methemoglobinemia is less responsive to treatment with methylene blue than nitrate- or nitrite-induced methemoglobinemia. This may explain, in part, the poor response to methylene blue by one of our patients.